InDex Pharmaceuticals Holding AB (publ) announced the composition of the nomination committee for the 2024 Annual General Meeting. The nomination committee for the 2024 Annual General Meeting of the company consists of: Karl Tobieson, appointed by Linc; Ivo Staijen, appointed by HBM Healthcare Investments; Jan Särlvik, appointed by Fjärde AP-fonden; Björn Wasing, appointed by SEB-Stiftelsen and S-E-Bankens Utvecklingsstiftelse; Wenche Rolfsen, Chairman of the Board (convener).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.473 SEK | -1.46% |
|
-5.21% | +87.50% |
14/06 | Alligator Bioscience Names New CFO | MT |
13/06 | InDex Pharmaceuticals Holding AB will Change its Name to Flerie AB | CI |
1st Jan change | Capi. | |
---|---|---|
+87.50% | 347M | |
+54.61% | 811B | |
+43.45% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.79% | 246B | |
+2.66% | 225B | |
+12.69% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- FLERIE Stock
- News Flerie Invest AB
- InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee